Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223385

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223385

APAC Breast Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 238 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Asia-Pacific breast cancer diagnostics market is projected to register a CAGR of 10.3% in the forecast period of 2023 to 2030. The new market report contains data for historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030.

Market Segmentation:

Asia-Pacific Breast Cancer Diagnostics Market, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centres, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, Japan, India, Australia, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the Asia-Pacific breast cancer diagnostics market are:

Increasing breast cancer patients among the women population as well as men

Rise in technological advancement for breast cancer diagnostic

Market Players

The key market players operating in the Asia-Pacific breast cancer diagnostics market are:

Provista Diagnostics

Thermo Fisher Scientific Inc.

Myriad Genetics, Inc.

Illumina, Inc.

Bio-Rad Laboratories, Inc.

BD

NanoString.

Cepheid

BIOMERIEUX

TABLE OF CONTENTS

1 INTRODUCTION 48

  • 1.1 OBJECTIVES OF THE STUDY 48
  • 1.2 MARKET DEFINITION 48
  • 1.3 OVERVIEW OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET 48
  • 1.4 CURRENCY AND PRICING 50
  • 1.5 LIMITATIONS 50
  • 1.6 MARKETS COVERED 50

2 MARKET SEGMENTATION 54

  • 2.1 MARKETS COVERED 54
  • 2.2 GEOGRAPHICAL SCOPE 55
  • 2.3 YEARS CONSIDERED FOR THE STUDY 56
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 57
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 60
  • 2.6 MULTIVARIATE MODELLING 61
  • 2.7 MARKET END USER COVERAGE GRID 62
  • 2.8 TEST TYPE LIFELINE CURVE 63
  • 2.9 DBMR MARKET POSITION GRID 64
  • 2.10 VENDOR SHARE ANALYSIS 65
  • 2.11 SECONDARY SOURCES 66
  • 2.12 ASSUMPTIONS 66

3 EXECUTIVE SUMMARY 67

4 PREMIUM INSIGHTS 69

  • 4.1 PESTEL ANALYSIS 70
  • 4.2 PORTER'S 5 FORCES 71

5 EPIDEMIOLOGY 72

6 INDUSTRIAL INSIGHTS 73

7 REGULATORY FRAMEWORK 74

8 MARKET OVERVIEW 76

  • 8.1 DRIVERS 78
    • 8.1.1 LAUNCH OF TECHNOLOGICALLY ADVANCED DIAGNOSIS & THERAPEUTICS TO AID GROWTH 78
    • 8.1.2 INCREASING PREVALENCE OF BREAST CANCER 78
    • 8.1.3 GROWING IMPORTANCE OF WOMEN'S HEALTH 79
    • 8.1.4 RISING AWARENESS TOWARDS THE BREAST CANCER 79
  • 8.2 RESTRAINTS 80
    • 8.2.1 ADVERSE EFFECTS OF BREAST CANCER THERAPEUTICS 80
    • 8.2.2 HIGH COST OF THE IMAGING SYSTEMS 80
  • 8.3 OPPORTUNITIES 81
    • 8.3.1 INITIATIVES TAKEN BY THE GOVERNMENT 81
    • 8.3.2 STRATEGIC INITIATIVES TAKEN BY THE KEY MARKET PLAYERS 81
    • 8.3.3 GROWTH IN RESEARCH AND DEVELOPMENT OF BREAST CANCER 82
  • 8.4 CHALLENGES 82
    • 8.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 82
    • 8.4.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF BREAST CANCER 83

9 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE 84

  • 9.1 OVERVIEW 85
  • 9.2 IMAGING 88
    • 9.2.1 IONIZING BREAST IMAGING TECHNOLOGIES 89
      • 9.2.1.1 FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM) 90
      • 9.2.1.2 ANALOG MAMMOGRAPHY 90
      • 9.2.1.3 3D BREAST TOMOSYNTHESIS 90
      • 9.2.1.4 POSITRON EMISSION TOMOGRAPHY/ COMPUTED TOMOGRAPHY (PET/CT) 90
      • 9.2.1.5 MOLECULAR BREAST IMAGING/ BREAST SPECIFIC GAMMA IMAGING (MBI/BSMI) 90
      • 9.2.1.6 POSITRON EMISSION MAMMOGRAPHY 90
      • 9.2.1.7 OTHERS 90
    • 9.2.2 NON-IONIZING IMAGING TECHNOLOGIES 90
      • 9.2.2.1 OPTICAL IMAGING 91
      • 9.2.2.2 BREAST ULTRASOUND 91
      • 9.2.2.3 BREAST MRI (MAGNETIC RESONANCE IMAGING) 91
      • 9.2.2.4 AUTOMATED WHOLE BREAST ULTRASOUND (AWBU) 91
      • 9.2.2.5 BREAST THERMOGRAPHY 92
    • 9.2.3 BIOPSY 92
      • 9.2.3.1 SURGICAL BIOPSY 93
      • 9.2.3.2 FINE NEEDLE ASPIRATION BIOPSY 93
      • 9.2.3.3 CORE NEEDLE BIOPSY 93
      • 9.2.3.4 IMAGE-GUIDED BIOPSY 93
      • 9.2.3.5 SENTINEL LYMPH NODE BIOPSY 94
    • 9.2.4 GENOMIC TEST 94
      • 9.2.4.1 MOLECULAR TESTING 95
        • 9.2.4.1.1 PD-L1 96
        • 9.2.4.1.2 MICROSATELLITE INSTABILITY-HIGH (MSI-H) OR DNA MISMATCH REPAIR DEFICIENCY (DMMR) 96
        • 9.2.4.1.3 NTRK GENE FUSIONS 96
        • 9.2.4.1.4 PI3KCA GENE MUTATION 96
      • 9.2.4.2 MAMMAPRINT 96
      • 9.2.4.3 ONCOTYPE DX 96
      • 9.2.4.4 OTHERS 96
  • 9.3 BLOOD TEST 97
  • 9.4 OTHERS 98

10 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE 99

  • 10.1 OVERVIEW 100
  • 10.2 INVASIVE DUCTAL CARCINOMA 103
  • 10.3 DUCTAL CARCINOMA IN SITU 103
  • 10.4 INFLAMMATORY BREAST CANCER 104
  • 10.5 METASTATIC BREAST CANCER 105

11 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER 106

  • 11.1 OVERVIEW 107
  • 11.2 HOSPITALS 109
  • 11.3 DIAGNOSTICS CENTERS 110
  • 11.4 CLINICS 111
  • 11.5 RESEARCH & ACADEMIC INSTITUTES 111
  • 11.6 OTHERS 112

12 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 114

  • 12.1 OVERVIEW 115
  • 12.2 DIRECT TENDER 118
  • 12.3 RETAIL SALES 118
  • 12.4 OTHERS 119

13 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY REGION 120

  • 13.1 ASIA-PACIFIC 121
    • 13.1.1 CHINA 130
    • 13.1.2 INDIA 136
    • 13.1.3 JAPAN 142
    • 13.1.4 INDONESIA 148
    • 13.1.5 PHILIPPINES 154
    • 13.1.6 THAILAND 160
    • 13.1.7 AUSTRALIA 166
    • 13.1.8 MALAYSIA 172
    • 13.1.9 SOUTH KOREA 178
    • 13.1.10 SINGAPORE 184
    • 13.1.11 REST OF ASIA-PACIFIC 190

14 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 191

  • 14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 191

15 SWOT ANALYSIS 192

16 COMPANY PROFILE 193

  • 16.1 HOLOGIC, INC. 193
    • 16.1.1 COMPANY SNAPSHOT 193
    • 16.1.2 REVENUE ANALYSIS 193
    • 16.1.3 COMPANY SHARE ANALYSIS 194
    • 16.1.4 PRODUCT PORTFOLIO 194
    • 16.1.5 RECENT DEVELOPMENTS 195
  • 16.2 SIEMENS HEALTHCARE GMBH 196
    • 16.2.1 COMPANY SNAPSHOT 196
    • 16.2.2 REVENUE ANALYSIS 197
    • 16.2.3 COMPANY SHARE ANALYSIS 197
    • 16.2.4 PRODUCT PORTFOLIO 198
    • 16.2.5 RECENT DEVELOPMENTS 198
  • 16.3 F. HOFFMANN- LA ROCHE LTD 199
    • 16.3.1 COMPANY SNAPSHOT 199
    • 16.3.2 REVENUE ANALYSIS 199
    • 16.3.3 COMPANY SHARE ANALYSIS 200
    • 16.3.4 PRODUCT PORTFOLIO 200
    • 16.3.5 RECENT DEVELOPMENTS 201
  • 16.4 KONINKLIJKE PHILIPS N.V. 202
    • 16.4.1 COMPANY SNAPSHOT 202
    • 16.4.2 REVENUE ANALYSIS 202
    • 16.4.3 COMPANY SHARE ANALYSIS 203
    • 16.4.4 PRODUCT PORTFOLIO 203
    • 16.4.5 RECENT DEVELOPMENTS 204
  • 16.5 ABBOTT 205
    • 16.5.1 COMPANY SNAPSHOT 205
    • 16.5.2 REVENUE ANALYSIS 205
    • 16.5.3 COMPANY SHARE ANALYSIS 206
    • 16.5.4 PRODUCT PORTFOLIO 206
    • 16.5.5 RECENT DEVELOPMENTS 206
  • 16.6 ABACUS ALS 207
    • 16.6.1 COMPANY SNAPSHOT 207
    • 16.6.2 PRODUCT PORTFOLIO 207
    • 16.6.3 RECENT DEVELOPMENTS 207
  • 16.7 BD 208
    • 16.7.1 COMPANY SNAPSHOT 208
    • 16.7.2 REVENUE ANALYSIS 208
    • 16.7.3 COMPANY SHARE ANALYSIS 209
    • 16.7.4 PRODUCT PORTFOLIO 209
    • 16.7.5 RECENT DEVELOPMENTS 209
  • 16.8 BIOCEPT, INC. 210
    • 16.8.1 COMPANY SNAPSHOT 210
    • 16.8.2 REVENUE ANALYSIS 210
    • 16.8.3 PRODUCT PORTFOLIO 211
    • 16.8.4 RECENT DEVELOPMENTS 211
  • 16.9 BIOMERIEUX 212
    • 16.9.1 COMPANY SNAPSHOT 212
    • 16.9.2 REVENUE ANALYSIS 212
    • 16.9.3 PRODUCT PORTFOLIO 213
    • 16.9.4 RECENT DEVELOPMENTS 213
  • 16.10 BIO-RAD LABORATORIES, INC. 214
    • 16.10.1 COMPANY SNAPSHOT 214
    • 16.10.2 REVENUE ANALYSIS 214
    • 16.10.3 PRODUCT PORTFOLIO 215
    • 16.10.4 RECENT DEVELOPMENT 215
  • 16.11 CEPHEID 216
    • 16.11.1 COMPANY SNAPSHOT 216
    • 16.11.2 REVENUE ANALYSIS 216
    • 16.11.3 PRODUCT PORTFOLIO 217
    • 16.11.4 RECENT DEVELOPMENT 217
  • 16.12 EXACT SCIENCES CORPORATION 218
    • 16.12.1 COMPANY SNAPSHOT 218
    • 16.12.2 REVENUE ANALYSIS 218
    • 16.12.3 COMPANY SHARE ANALYSIS 219
    • 16.12.4 PRODUCT PORTFOLIO 219
    • 16.12.5 RECENT DEVELOPMENTS 220
  • 16.13 FUJIFILM CORPORATION 221
    • 16.13.1 COMPANY SNAPSHOT 221
    • 16.13.2 REVENUE ANALYSIS 221
    • 16.13.3 PRODUCT PORTFOLIO 222
    • 16.13.4 RECENT DEVELOPMENT 222
  • 16.14 GENERAL ELECTRIC 223
    • 16.14.1 COMPANY SNAPSHOT 223
    • 16.14.2 REVENUE ANALYSIS 223
    • 16.14.3 PRODUCT PORTFOLIO 224
    • 16.14.4 RECENT DEVELOPMENTS 224
  • 16.15 ILLUMINA, INC. 225
    • 16.15.1 COMPANY SNAPSHOT 225
    • 16.15.2 REVENUE ANALYSIS 225
    • 16.15.3 PRODUCT PORTFOLIO 226
    • 16.15.4 RECENT DEVELOPMENTS 226
  • 16.16 MYRIAD GENETICS, INC. 227
    • 16.16.1 COMPANY SNAPSHOT 227
    • 16.16.2 REVENUE ANALYSIS 227
    • 16.16.3 PRODUCT PORTFOLIO 228
    • 16.16.4 RECENT DEVELOPMENT 228
  • 16.17 NANOSTRING. 229
    • 16.17.1 COMPANY SNAPSHOT 229
    • 16.17.2 REVENUE ANALYSIS 229
    • 16.17.3 PRODUCT PORTFOLIO 230
    • 16.17.4 RECENT DEVELOPMENT 230
    • 16.17.5 RECENT DEVELOPMENT 230
  • 16.18 ONCOSTEM. 231
    • 16.18.1 COMPANY SNAPSHOT 231
    • 16.18.2 PRODUCT PORTFOLIO 231
    • 16.18.3 RECENT DEVELOPMENT 231
  • 16.19 PROVISTA DIAGNOSTICS. 232
    • 16.19.1 COMPANY SNAPSHOT 232
    • 16.19.2 PRODUCT PORTFOLIO 232
    • 16.19.3 RECENT DEVELOPMENT 232
  • 16.20 THERMO FISHER SCIENTIFIC INC. 233
    • 16.20.1 COMPANY SNAPSHOT 233
    • 16.20.2 REVENUE ANALYSIS 233
    • 16.20.3 PRODUCT PORTFOLIO 234
    • 16.20.4 RECENT DEVELOPMENT 234

17 QUESTIONNAIRE 235

18 RELATED REPORTS 238

LIST OF TABLES

  • TABLE 1 INCIDENCE RATE OF BREAST CANCER (2020) 49
  • TABLE 2 MORTALITY RATE OF BREAST CANCER (2020) 49
  • TABLE 3 INCIDENCE OF DUCTAL CARCINOMA IN SITU (DCIS) BREAST CANCER 49
  • TABLE 4 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 64
  • TABLE 5 ASIA PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 65
  • TABLE 6 ASIA PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 65
  • TABLE 7 ASIA PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 66
  • TABLE 8 ASIA PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 66
  • TABLE 9 ASIA PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 68
  • TABLE 10 ASIA PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 68
  • TABLE 11 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 69
  • TABLE 12 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 70
  • TABLE 13 ASIA PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 70
  • TABLE 14 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 71
  • TABLE 15 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 72
  • TABLE 16 ASIA PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 72
  • TABLE 17 ASIA PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 72
  • TABLE 18 ASIA PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 73
  • TABLE 19 ASIA PACIFIC BLOOD TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 74
  • TABLE 20 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 75
  • TABLE 21 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 79
  • TABLE 22 ASIA PACIFIC INVASIVE DUCTAL CARCINOMA IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 80
  • TABLE 23 ASIA PACIFIC DUCTAL CARCINOMA IN SITU IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 81
  • TABLE 24 ASIA PACIFIC INFLAMMATORY BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 25 ASIA PACIFIC METASTATIC BREAST CANCER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 26 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 86
  • TABLE 27 ASIA PACIFIC HOSPITALS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
  • TABLE 28 ASIA PACIFIC DIAGNOSTIC CENTERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 87
  • TABLE 29 ASIA PACIFIC CLINICS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
  • TABLE 30 ASIA PACIFIC RESEARCH AND ACADEMIC INSTITUTES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 31 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 90
  • TABLE 32 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 94
  • TABLE 33 ASIA PACIFIC DIRECT TENDER IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
  • TABLE 34 ASIA PACIFIC RETAIL SALES IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
  • TABLE 35 ASIA PACIFIC OTHERS IN BREAST CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
  • TABLE 36 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 102
  • TABLE 37 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 38 ASIA-PACIFIC IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 102
  • TABLE 39 ASIA-PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 40 ASIA-PACIFIC IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 103
  • TABLE 41 ASIA-PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 42 ASIA-PACIFIC NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 104
  • TABLE 43 ASIA-PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 44 ASIA-PACIFIC BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 104
  • TABLE 45 ASIA-PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 46 ASIA-PACIFIC GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
  • TABLE 47 ASIA-PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 48 ASIA-PACIFIC MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 105
  • TABLE 49 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 105
  • TABLE 50 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 106
  • TABLE 51 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 106
  • TABLE 52 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 53 CHINA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 54 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 55 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 108
  • TABLE 56 CHINA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 108
  • TABLE 57 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 108
  • TABLE 58 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 109
  • TABLE 59 CHINA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 109
  • TABLE 60 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 109
  • TABLE 61 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 109
  • TABLE 62 CHINA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 110
  • TABLE 63 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 64 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 110
  • TABLE 65 CHINA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 110
  • TABLE 66 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 110
  • TABLE 67 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 111
  • TABLE 68 CHINA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 111
  • TABLE 69 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 111
  • TABLE 70 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 111
  • TABLE 71 CHINA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 112
  • TABLE 72 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 73 INDIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 74 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 113
  • TABLE 75 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 114
  • TABLE 76 INDIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 114
  • TABLE 77 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 114
  • TABLE 78 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 115
  • TABLE 79 INDIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 115
  • TABLE 80 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 115
  • TABLE 81 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 115
  • TABLE 82 INDIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 116
  • TABLE 83 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 84 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 116
  • TABLE 85 INDIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 116
  • TABLE 86 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 116
  • TABLE 87 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 117
  • TABLE 88 INDIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 117
  • TABLE 89 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
  • TABLE 90 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 117
  • TABLE 91 INDIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 118
  • TABLE 92 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 93 JAPAN IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 94 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 119
  • TABLE 95 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 120
  • TABLE 96 JAPAN IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 120
  • TABLE 97 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 120
  • TABLE 98 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 121
  • TABLE 99 JAPAN NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 121
  • TABLE 100 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 121
  • TABLE 101 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 121
  • TABLE 102 JAPAN BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 122
  • TABLE 103 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 104 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 122
  • TABLE 105 JAPAN GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 122
  • TABLE 106 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 122
  • TABLE 107 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 123
  • TABLE 108 JAPAN MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 123
  • TABLE 109 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
  • TABLE 110 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 123
  • TABLE 111 JAPAN BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 124
  • TABLE 112 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 113 INDONESIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 114 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 125
  • TABLE 115 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 126
  • TABLE 116 INDONESIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 126
  • TABLE 117 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 126
  • TABLE 118 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 127
  • TABLE 119 INDONESIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 127
  • TABLE 120 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 127
  • TABLE 121 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 127
  • TABLE 122 INDONESIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 128
  • TABLE 123 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 124 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 128
  • TABLE 125 INDONESIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 128
  • TABLE 126 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 128
  • TABLE 127 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 129
  • TABLE 128 INDONESIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 129
  • TABLE 129 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 129
  • TABLE 130 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 129
  • TABLE 131 INDONESIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 130
  • TABLE 132 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 133 PHILIPPINES IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 134 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 131
  • TABLE 135 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 132
  • TABLE 136 PHILIPPINES IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 132
  • TABLE 137 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 132
  • TABLE 138 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 133
  • TABLE 139 PHILIPPINES NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 133
  • TABLE 140 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 133
  • TABLE 141 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 133
  • TABLE 142 PHILIPPINES BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 134
  • TABLE 143 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 144 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 134
  • TABLE 145 PHILIPPINES GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 134
  • TABLE 146 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 134
  • TABLE 147 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 135
  • TABLE 148 PHILIPPINES MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 135
  • TABLE 149 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 135
  • TABLE 150 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 135
  • TABLE 151 PHILIPPINES BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 136
  • TABLE 152 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 153 THAILAND IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 154 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 137
  • TABLE 155 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 138
  • TABLE 156 THAILAND IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 138
  • TABLE 157 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 138
  • TABLE 158 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 139
  • TABLE 159 THAILAND NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 139
  • TABLE 160 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 139
  • TABLE 161 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 139
  • TABLE 162 THAILAND BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 140
  • TABLE 163 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 164 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 140
  • TABLE 165 THAILAND GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 140
  • TABLE 166 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 140
  • TABLE 167 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 141
  • TABLE 168 THAILAND MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 141
  • TABLE 169 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 141
  • TABLE 170 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 141
  • TABLE 171 THAILAND BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 142
  • TABLE 172 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 173 AUSTRALIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 174 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 143
  • TABLE 175 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 144
  • TABLE 176 AUSTRALIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 144
  • TABLE 177 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 144
  • TABLE 178 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 145
  • TABLE 179 AUSTRALIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 145
  • TABLE 180 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 145
  • TABLE 181 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 145
  • TABLE 182 AUSTRALIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 146
  • TABLE 183 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 184 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 146
  • TABLE 185 AUSTRALIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 146
  • TABLE 186 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 146
  • TABLE 187 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 147
  • TABLE 188 AUSTRALIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 147
  • TABLE 189 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 147
  • TABLE 190 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 147
  • TABLE 191 AUSTRALIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 148
  • TABLE 192 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 193 MALAYSIA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 194 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 149
  • TABLE 195 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 150
  • TABLE 196 MALAYSIA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 150
  • TABLE 197 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 150
  • TABLE 198 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 151
  • TABLE 199 MALAYSIA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 151
  • TABLE 200 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 151
  • TABLE 201 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 151
  • TABLE 202 MALAYSIA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 152
  • TABLE 203 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 204 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 152
  • TABLE 205 MALAYSIA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 152
  • TABLE 206 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 152
  • TABLE 207 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 153
  • TABLE 208 MALAYSIA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 153
  • TABLE 209 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 153
  • TABLE 210 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 153
  • TABLE 211 MALAYSIA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 154
  • TABLE 212 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 213 SOUTH KOREA IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 214 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 155
  • TABLE 215 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 156
  • TABLE 216 SOUTH KOREA IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 156
  • TABLE 217 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 156
  • TABLE 218 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 157
  • TABLE 219 SOUTH KOREA NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 157
  • TABLE 220 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 157
  • TABLE 221 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 157
  • TABLE 222 SOUTH KOREA BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 158
  • TABLE 223 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 224 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 158
  • TABLE 225 SOUTH KOREA GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 158
  • TABLE 226 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 158
  • TABLE 227 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 159
  • TABLE 228 SOUTH KOREA MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 159
  • TABLE 229 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 159
  • TABLE 230 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 159
  • TABLE 231 SOUTH KOREA BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 160
  • TABLE 232 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 233 SINGAPORE IMAGING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 234 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 235 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 162
  • TABLE 236 SINGAPORE IONIZING BREAST IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 162
  • TABLE 237 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 238 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 163
  • TABLE 239 SINGAPORE NON-IONIZING IMAGING TECHNOLOGIES IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 163
  • TABLE 240 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 241 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 163
  • TABLE 242 SINGAPORE BIOPSY IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 164
  • TABLE 243 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 244 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 164
  • TABLE 245 SINGAPORE GENOMIC TEST IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 164
  • TABLE 246 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 247 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 ASP 165
  • TABLE 248 SINGAPORE MOLECULAR TESTING IN BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (UNITS) 165
  • TABLE 249 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION) 165
  • TABLE 250 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 165
  • TABLE 251 SINGAPORE BREAST CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 166
  • TABLE 252 REST OF ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 167

LIST OF FIGURES

  • FIGURE 1 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 30
  • FIGURE 2 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION 33
  • FIGURE 3 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DROC ANALYSIS 34
  • FIGURE 4 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS 35
  • FIGURE 5 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS 35
  • FIGURE 6 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS 36
  • FIGURE 7 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: MARKET END USER COVERAGE GRID 38
  • FIGURE 8 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID 40
  • FIGURE 9 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS 41
  • FIGURE 10 ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET: SEGMENTATION 44
  • FIGURE 11 GROWING AWARENESS OF BREAST CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030 45
  • FIGURE 12 THE IMAGING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTIC MARKET IN 2023 & 2030 45
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET 53
  • FIGURE 14 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 61
  • FIGURE 15 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 62
  • FIGURE 16 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 62
  • FIGURE 17 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 63
  • FIGURE 18 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2022 76
  • FIGURE 19 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, 2023-2030 (USD MILLION) 77
  • FIGURE 20 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, CAGR (2023-2030) 77
  • FIGURE 21 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY TYPE, LIFELINE CURVE 78
  • FIGURE 22 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2022 83
  • FIGURE 23 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 84
  • FIGURE 24 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 84
  • FIGURE 25 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 85
  • FIGURE 26 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 91
  • FIGURE 27 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 92
  • FIGURE 28 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 92
  • FIGURE 29 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 93
  • FIGURE 30 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 98
  • FIGURE 31 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 99
  • FIGURE 32 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 99
  • FIGURE 33 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 100
  • FIGURE 34 ASIA-PACIFIC BREAST CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 100
  • FIGURE 35 ASIA PACIFIC BREAST CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 167
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!